

**USSN 08/700,565
GRUENBERG
AMENDMENT**

Claims 22-25, 28, 29, 31-33, 155-158, 164-168 and 170-172, 211, 212, 213, 216 and 217 are pending.

A clean copy of claim 211, as requested, is provided herewith. Claim 211 was amended in the Amendment filed, 08/15/01, in Response to the Office Action mailed on February 13, 2001, with only the marked-up version of the claim enclosed.

A marked up copy of claim 211 showing the amendment originally filed on 8/15/01 is appended hereto.

* * *


In view of the above remarks and the amendments and remarks of record, consideration and allowance of the application are respectfully requested.

Respectfully submitted,
HELLER EHRMAN WHITE & MCAULIFFE LLP

By: _____


Stephanie Seidman
Registration No. 33,779

Attorney Docket No. 24731-500B
Address all correspondence to:
HELLER EHRMAN WHITE & MCAULIFFE LLP
4350 La Jolla Village Drive
San Diego, CA 92122-9164
Telephone: 858 450-8400
Facsimile: 858 587-5360



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: MICHEAL L. GRUENBERG

Serial No.: 08/700,565

Filed: July 25, 1996

For: AUTOLOGOUS IMMUNE CELL
THERAPY: CELL COMPOSITIONS,
METHODS AND APPLICATIONS TO
TREATMENT OF HUMAN DISEASE

Art Unit: 1644

Examiner: Schwadron, R

I hereby certify that this paper and the attached
papers are being deposited with the United
States Postal Service as First Class mail in an
envelope addressed to:

Commissioner for Patents
Washington, D.C. 20231, on this date.

11/14/01
Date

Kelly Fischer
Kelly Fischer
RECEIVED
FEB 04 2002
TECHNICAL CENTER 1600/2900

MARKED UP CLAIMS (37 C.F.R. § 1.121)

Please amend claim 211 as follows:

211. (Twice Amended) A method for generating immune cells for
autologous cellular immunotherapy, comprising:
collecting leukocyte containing material from a mammal;
differentiating the leukocytes into Th1 [or Th2] cells; and
exposing the leukocyte containing material to two or more mitogenic
monoclonal antibodies to induce *in vitro* cell proliferation sufficient for infusion into
the mammal for use in an immunotherapy treatment, wherein the *in vitro* cell
proliferation is produced without the use of exogenous interleukin-2.